PCDH10: Identifying Potential Drug Targets (G57575)

Target Name: PCDH10

NCBI ID: G57575

PCDH10

PCDH10: Identifying Potential Drug Targets

PCDH10 (Protamineuronucleic Acid Deficiency 10) is a rare autosomal recessive disorder that is characterized by the absence of protamineuronucleic acid (PNA) in the brain. PNA is a crucial component of the brain and is responsible for maintaining the structure and function of nerve cells. The absence of PNA leads to a range of developmental and cognitive impairments, including delays in language development, decreased visual acuity, and progressive motor neuron weakness.

The exact cause of PCDH10 is not known, but it is thought to be caused by a genetic mutation that affects the production of the protein NAG2. NAG2 is a negative regulator of the neurotransmitter dopamine and is involved in the development and maintenance of normal brain function . In individuals with PCDH10, the absence of NAG2 leads to an accumulation of toxic N-methyl-D-aspartate (NMDA) in the brain, which can cause damage to the brain cells and contribute to the development of the disorder.

Despite the efforts of researchers to identify a potential drug target for PCDH10, there is currently no approved treatment available. The only way to treat the disorder is to provide supportive care, such as physical therapy and occupational therapy, to help individuals with the disorder manage their symptoms.

However, recent studies have identified potential drug targets for PCDH10 that may be able to treat the disorder. One potential target is the protein known as KIAA1400, which is a key regulator of the growth and development of neurons. Researchers have identified a missense mutation in the KIAA1400 gene that is associated with the development of PCDH10.

The missense mutation has led to the production of a protein that is shorter than the normal KIAA1400 protein. This shorter protein is not functional, as it does not contain the full length of the original protein. The absence of the full-length protein has led to a reduction in the level of KIAA1400 in the brain, which may contribute to the development of PCDH10.

Another potential drug target for PCDH10 is the protein known as Egr-1. Egr-1 is a transcription factor that is involved in the regulation of gene expression and has been implicated in the development of various neurological disorders. Researchers have identified a missense mutation in the Egr-1 gene that is associated with the development of PCDH10.

The missense mutation has led to the production of a protein that is shorter than the normal Egr-1 protein. This shorter protein is not functional, as it does not contain the full length of the original protein. The absence of the full-length protein has led to a reduction in the level of Egr-1 in the brain, which may contribute to the development of PCDH10.

While the identification of potential drug targets for PCDH10 is an important step in the development of treatments for the disorder, further research is needed to determine the effectiveness of these targets. Additionally, the development of new treatments for PCDH10 will require the collaboration of multiple researchers and the funding of significant financial resources.

In conclusion, PCDH10 is a rare autosomal recessive disorder that is characterized by the absence of protamineuronucleic acid (PNA) in the brain. The disorder is caused by the production of a shorter version of the protein NAG2, which can cause damage to the brain cells and contribute to the development of the disorder. While the identification of potential drug targets for PCDH10 is an important step in the development of treatments for the disorder, further research is needed to determine their effectiveness.

Protein Name: Protocadherin 10

Functions: Potential calcium-dependent cell-adhesion protein

The "PCDH10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDH10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets